ReviewCurrent cardiology reviews2011
Cardiotoxicity of molecularly targeted agents.
Review in Current cardiology reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case-Control Study.Journal of the American Heart Association · 2024Observational
- Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2024Article
- Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.Cancer chemotherapy and pharmacology · 2023Article
- Prediction of drug-induced liver injury and cardiotoxicity using chemical structure and in vitro assay data.Toxicology and applied pharmacology · 2022Article
- Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery.Expert opinion on drug discovery · 2022Review
- Cancer Therapies and Vascular Toxicities.Current treatment options in oncology · 2022Review
- Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography.American heart journal plus : cardiology research and practice · 2022Article
- Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors.Frontiers in oncology · 2022Review
- Interactions between cardiology and oncology drugs in precision cardio-oncology.Clinical science (London, England : 1979) · 2021Review
- Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Medicinal research reviews · 2018Review
- Vascular Complications of Cancer Chemotherapy.The Canadian journal of cardiology · 2016Review
- A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.Experimental biology and medicine (Maywood, N.J.) · 2014Review
- Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.SpringerPlus · 2014Article
- Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.Current cardiology reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiac toxicity of molecularly targeted cancer agents is increasingly recognized as a significant side effect of chemotherapy. These new potent therapies may not only affect the survival of cancer cells, but have the potential to adversely impact normal cardiac and vascular function. Unraveling the mechanisms by which these therapies affect the heart and vasculature is crucial for improving drug design and finding alternative therapies to protect patients predisposed to cardiovascular disease. In this review, we summarize the classification and side effects of currently approved molecularly targeted chemotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.